

Aerogen leading the way for inhaled vaccine delivery

Company's aerosol drug delivery technology used in Phase 1 clinical trial to deliver inhaled type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults without COVID-19 from China

The Aerogen Solo is a closed-system, single-patient-use aerosol drug delivery technology¹ that mitigates the transmission of patient-generated infectious aerosol during ventilation²⁻⁷.

Hospitals around the world have been using Aerogen's closed-circuit nebuliser technology to deliver aerosolised medication to critically ill ventilated Covid-19 patients, with over 3 million patients being treated with Aerogen in 2020⁸.

The company formed a Covid response unit in March 2020 to support projects researching potential treatments and vaccines and is now working with global pharmaceutical companies on the safe delivery of inhaled therapies. Aerogen's technology is being used in several clinical trials⁸. Details of the most recent trial being published this week in the Lancet.

Aerogen's innovative aerosol drug delivery technology was used in a Phase 1 clinical trial to deliver inhaled type-5 vector-based COVID-19 vaccine (Ad5-nCoV) to adults without COVID-19 in China⁹. The Aerogen Ultra device was adapted to facilitate the study⁹.

The study concluded that the aerosol inhalation of Ad5-nCoV is painless, simple, well tolerated, and immunogenic, and the current data supports the evaluation of aerosolised Ad5-nCoV in ongoing phase 2 and 3 clinical trials⁹. The efficacy and cost-effectiveness of aerosol vaccination should be evaluated in future studies⁹.

For further information on the study [click here](#).

About:

Aerogen is the world leader in acute care aerosol drug delivery. The Aerogen Solo is a closed-system, single-patient-use aerosol drug delivery technology¹ that mitigates the transmission of patient-generated infectious aerosol during ventilation²⁻⁷. As the only globally available closed-circuit system, Aerogen technology has been used to treat over 13 million patients in 75 countries worldwide, playing a critical role in emergency departments and intensive care units⁸.

For more information on Aerogen visit Aerogen.com.

PM1003

References

- 1 Aerogen Solo System Instruction Manual. Aerogen Ltd. P/N 30-354, Revision U.
- 2 Ari A. Practical strategies for a safe and effective delivery of aerosolized medications to patients with COVID-19. *Respir. Med.* 2020; 167. doi:10.1016/j.rmed.2020.105987.
- 3 Miller A, Epstein D. Safe bronchodilator treatment in mechanically ventilated COVID-19 patients: A single center experience. *J. Crit. Care.* 2020; 58: 56–57.
- 4 Fink JB, Ehrmann S, Li J, Dailey P, McKiernan P, Darquenne C *et al.* Reducing Aerosol-Related Risk of Transmission in the Era of COVID-19: An Interim Guidance Endorsed by the International Society of Aerosols in Medicine. *J Aerosol Med Pulm Drug Deliv* 2020. doi:10.1089/jamp.2020.1615.
- 5 Halpin DMG, Criner GJ, Papi A, Singh D, Anzueto A, Martinez FJ *et al.* Global Initiative for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: The 2020 GOLD Science Committee Report on COVID-19 & COPD. *Am J Respir Crit Care Med* 2020. doi:10.1164/rccm.202009-3533SO.
- 6 O'Toole C, McGrath JA, Joyce M, Bennett G, Byrne MA, MacLoughlin R. Fugitive Aerosol Therapy Emissions during Mechanical Ventilation: In Vitro Assessment of the Effect of Tidal Volume and Use of Protective Filters. *Aerosol Air Qual Res* 2020; 20. doi:10.4209/aaqr.2020.04.0176.
- 7 Joyce M, McGrath JA, Mac Giolla Eain M, O'Sullivan A, Byrne M, MacLoughlin R. Nebuliser Type Influences Both Patient-Derived Bioaerosol Emissions and Ventilation Parameters during Mechanical Ventilation. *Pharmaceutics* 2021; 13: 199.
- 8 Aerogen Internal data on File.
- 9 Wu S, Huang J, Zhang Z, Wu J, Zhang J, Hu H *et al.* Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial. *Lancet Infect Dis* 2021; 0. doi:10.1016/S1473-3099(21)00396-0.